Mark David Van Oene

Senior Vice President & Chief Commercial Officer at Illumina, Inc.

Mark David Van Oene

Mark David Van Oene

Senior Vice President & Chief Commercial Officer at Illumina, Inc.

Biography

Mark Van Oene

Senior Vice President & Chief Commercial Officer

Mark Van Oene is Senior Vice President and Chief Commercial Officer for Illumina, a position he has held since 2017. Presently, Van Oene is also the acting General Manager for Greater China. He is responsible for the development and implementation of the company’s commercial strategy and is responsible for world-wide sales, services and marketing. Van Oene was previously Illumina’s Senior Vice President of the Americas region and subsequently named interim Chief Commercial Officer in late 2016. Van Oene joined Illumina in 2006 as Regional Account Manager for Canada. In 2008, he assumed the role of Senior Director of Sales for the Americas and was promoted to Vice President with responsibility for global sales in 2012. In early 2014, Van Oene was named the General Manager for the Americas region, advancing to Senior Vice President in April 2016.

Prior to Illumina, Van Oene was Director, Genotyping Services for Ellipsis Biotherapeutics.

Van Oene earned a B.S. in biochemistry from Western University and was a Ph.D. candidate at the University of Toronto in Molecular and Medical Genetics.

Overview
RelSci Relationships

899

Number of Boards

3

Birthday

1972

Age

47

Relationships
RelSci Relationships are individuals Mark David Van Oene likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at Illumina, Inc.

Relationship likelihood: Strong

Senior Vice President & General Manager, Commercial Operations-Europe, Middle East & Africa at Illumina, Inc.

Relationship likelihood: Strong

Former President & Chief Executive Officer at Illumina, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Helix Opco LLC

Relationship likelihood: Strong

Co-Founder at Quanterix Corp.

Relationship likelihood: Strong

Former General Accounting Manager at Sugen LLC

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Verogen, Inc.

Relationship likelihood: Strong

Diagnostics at DNA Direct, Inc.

Relationship likelihood: Strong

Senior Vice President, General Counsel & Secretary at Illumina, Inc.

Relationship likelihood: Strong

Senior Vice President & Chief Technology Officer at Illumina, Inc.

Relationship likelihood: Strong

Paths to Mark David Van Oene
Potential Connections via
Relationship Science
You
Mark David Van Oene
Senior Vice President & Chief Commercial Officer at Illumina, Inc.
Education

The University of Western Ontario, which is commonly referred to among Canadian universities as Western, is a public research university located in London, Ontario, Canada. The university's main campus covers 455 hectares (1,120 acres) of land, with the Thames River running through the eastern portion. The university was founded on 7 March 1878 by Bishop Isaac Hellmuth of the Anglican Diocese of Huron as "The Western University of London Ontario." It incorporated Huron University College, which had been founded in 1863.

Career History
Senior Vice President & Chief Commercial Officer
2006 - Current

Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Director-Genotyping Services
Prior

Ellipsis Biotherapeutics Corp., part of DNAPrint Genomics, Inc., is a company headquartered in Toronto, ON, Canada. The firm provides commercial genotyping services and gene research. On 19 Dec 05 DNAPrint Genomics, Inc. acquired Ellipsis Biotherapeutics Corp. for $0.11 million.

Public Holdings
Restricted data only for RelSci Professional users.
Other Affiliations

Mark David Van Oene is affiliated with Illumina, Inc., Ellipsis Biotherapeutics Corp.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Mark David Van Oene. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Mark David Van Oene's profile does not indicate a business or promotional relationship of any kind between RelSci and Mark David Van Oene.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/mark-david-van-oene-211887555
  • https://relationshipscience.com/person/mark-david-van-oene-211887555